Bad Drug List
Home / Bad Drugs / Rezulin

Rezulin

Rezulin diabetes drug was recalled on March 21, 2000 after a controversial FDA approval and stay on the U.S. market. Linked to 90 cases of life threatening liver damage, at least 63 deaths have resulted from the use of this diabetes drug. Approved on the FDA's "fast track" in just six months, FDA physicians describe the approval conditions as lowered safety standards. The L.A. Times had reported on the Rezulin scandal after a whistleblower showed internal FDA email messages to one of the reporters. Rezulin had been prescribed to an estimated 2 million people prior to the Rezulin recall.

The FDA doctor considered the top expert in assessing and preventing deaths related to the use of prescription drugs concluded that Rezulin patients are 1,200 times more likely to suffer liver failure. Approved to treat type-2 diabetes, Rezulin manufacturer Warner-Lambert has been accused of knowing as early as 1993 of at least one case of a patient who showed liver damage after taking Rezulin. The L.A. Times reported the Rezulin manufacturer downplayed liver damage concerns when seeking federal approval by assuring Rezulin was low risk.

If you have taken the diabetes drug Rezulin and would like to learn more about your legal rights and options please contact us.

MedLine Plus Drug Information - Guide to prescription and over-the-counter medications provided by the United States Pharmacopeia.

DiabetesMonitor.com - Rezulin® (troglitazone) was voluntarily withdrawn from the market by the manufacturer on March 21, 2000.